Autolus Therapeutics Earnings Announcement Scheduled
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 4 days ago
0mins
Should l Buy AUTL?
Source: seekingalpha
- Earnings Release Date: Autolus Therapeutics is set to announce its FY earnings on March 27 before market open, with investors keenly awaiting performance insights to gauge future growth potential.
- EPS Expectations: The consensus EPS estimate stands at -$0.43, reflecting a 50% year-over-year improvement, indicating the company's efforts to enhance profitability, albeit still facing losses.
- Significant Revenue Growth: The consensus revenue estimate is $74.75 million, representing a substantial year-over-year increase of 638.6%, showcasing the company's strong performance in market demand and product sales.
- Performance Revision Insights: Over the past year, Autolus has only beaten EPS estimates 25% of the time, with no revenue estimates surpassed, highlighting market uncertainty regarding its profitability trajectory.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AUTL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AUTL
Wall Street analysts forecast AUTL stock price to rise
5 Analyst Rating
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 1.210
Low
5.00
Averages
7.18
High
10.00
Current: 1.210
Low
5.00
Averages
7.18
High
10.00
About AUTL
Autolus Therapeutics plc is a United Kingdom-based early commercial-stage biopharmaceutical company developing programmed T cell therapies for the treatment of cancer and autoimmune diseases. The Company has an approved commercial product, AUCATZYL, for the treatment of adult patients with r/r B-ALL. Using a suite of proprietary and modular T cell programming technologies, it is also developing five programs in seven hematological and solid tumor indications and one autoimmune indication. It is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and attack and eliminate these cells. Its product pipeline includes obe-cel (ALLCAR19), obe-cel (CAROUSEL), AUTO1/22 (CARPALL), AUTO4 (LibrA T1), AUTO6 (MAGNETO), AUTO5, AUTO8 (MCARTY) and AUTO9. AUTO4 and AUTO5 are two programmed T cell therapies for the treatment of peripheral T-cell lymphoma targeting TRBC 1 and TRBC 2.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Autolus Therapeutics Reports Strong 2025 Earnings with AUCATZYL Launch Success
- AUCATZYL Sales Performance: Autolus Therapeutics achieved $74.3 million in AUCATZYL sales for 2025, marking a successful U.S. launch with 67 centers activated by year-end, indicating strong market demand and positive physician feedback.
- 2026 Financial Outlook: Management reiterated guidance for 2026 net revenue between $120 million and $135 million, expecting a shift to positive gross margins and activation of over 80 centers by year-end, reflecting confidence in future growth.
- Clinical Data Support: The ROCCA Consortium reported a 92% overall complete remission rate at day 28 for 91 patients treated with AUCATZYL, closely aligning with prior clinical trial data, which further bolsters physician confidence and market acceptance.
- R&D and Financial Status: Q4 2025 net product revenue was $23.3 million, with R&D expenses at $35.6 million; despite an operating loss of $72.5 million, the company maintains $300.7 million in cash and equivalents, sufficient to fund operations into Q4 2027.
See More
AUCATZYL® 2025 Financial Results and Market Outlook
- Revenue Growth: AUCATZYL® reported net product revenue of $23.3 million for Q4 2025 and $74.3 million for the full year, indicating strong demand in the U.S. market, which is expected to drive future revenue growth for Autolus.
- UK Market Launch: Following a successful evaluation by the National Institute for Health and Care Excellence (NICE), AUCATZYL® was launched in the UK in January 2026, marking a significant step in the company's international expansion strategy and is anticipated to further enhance market share.
- Positive Outlook: Autolus projects net product revenue for AUCATZYL® to range between $120 million and $135 million in 2026, with expectations of achieving a positive gross margin, reflecting positive changes in operational efficiency and market demand.
- Clinical Trial Progress: AUCATZYL® has demonstrated a favorable safety and efficacy profile in multiple clinical trials, particularly in pediatric patients with relapsed/refractory B-ALL, where preliminary data shows an overall response rate of 95.5%, laying a solid foundation for future market promotion.
See More
Autolus Therapeutics Q4 Earnings Report Analysis
- Disappointing Earnings: Autolus Therapeutics reported a Q4 GAAP EPS of -$0.34, missing expectations by $0.07, indicating challenges in profitability that may affect investor confidence.
- Revenue Beat: Despite the EPS miss, Q4 revenue reached $24.29 million, exceeding market expectations by $0.37 million, suggesting that the company still possesses some growth potential in sales.
- Cautious Future Outlook: As FY 2025 earnings approach, market expectations regarding Autolus's profitability and revenue growth will be closely monitored, requiring investors to assess the company's positioning in the competitive biopharmaceutical market.
- Analyst Rating Dynamics: Seeking Alpha's Quant Rating on Autolus Therapeutics reflects market divergence regarding its future performance, highlighting differing investor perspectives on the company's long-term strategy and financial health.
See More
Autolus Therapeutics Earnings Announcement Scheduled
- Earnings Release Date: Autolus Therapeutics is set to announce its FY earnings on March 27 before market open, with investors keenly awaiting performance insights to gauge future growth potential.
- EPS Expectations: The consensus EPS estimate stands at -$0.43, reflecting a 50% year-over-year improvement, indicating the company's efforts to enhance profitability, albeit still facing losses.
- Significant Revenue Growth: The consensus revenue estimate is $74.75 million, representing a substantial year-over-year increase of 638.6%, showcasing the company's strong performance in market demand and product sales.
- Performance Revision Insights: Over the past year, Autolus has only beaten EPS estimates 25% of the time, with no revenue estimates surpassed, highlighting market uncertainty regarding its profitability trajectory.
See More
Precision Biologics Market Awakens to $71 Billion Opportunity
- FDA Acceleration: Oncolytics Biotech's cancer treatment pelareorep has received Fast Track Designation from the FDA for KRAS-mutant microsatellite-stable metastatic colorectal cancer patients, demonstrating a 33% response rate significantly higher than the 10% seen with traditional chemotherapy, which will expedite its approval process and enhance market competitiveness.
- Survival Extension: Clinical data shows that patients treated with pelareorep have a median survival of 27 months compared to 11.2 months with standard treatment, indicating the drug's potential market value in hard-to-treat cancer populations, with the global second-line treatment market estimated between $3 billion and $5 billion annually.
- Leadership Team Expansion: Oncolytics Biotech recently appointed John McAdory as Executive Vice President of Strategy and Operations and Yujun Wu as Vice President of Biostatistics to manage expanding clinical programs, reflecting the company's commitment to future growth and readiness.
- Clinical Trial Plans: The company plans to launch a controlled study in March 2026 comparing standard treatment with pelareorep, with interim data expected by year-end, further validating its efficacy in colorectal cancer treatment.
See More
Precision Biologics Market Awakens to $71 Billion Opportunity
- FDA Acceleration: Oncolytics Biotech's cancer treatment pelareorep has received Fast Track Designation from the FDA for KRAS-mutant microsatellite-stable metastatic colorectal cancer patients, demonstrating a 33% response rate, significantly higher than the 10% achieved with traditional chemotherapy, which will expedite its market entry and enhance the company's position in the competitive biopharmaceutical sector.
- Significant Survival Extension: Clinical data shows that patients treated with pelareorep have a median survival of 27 months compared to 11.2 months with standard treatment, indicating the drug's potential market value in hard-to-treat cancer populations, with the global second-line treatment market estimated between $3 billion and $5 billion annually.
- Clinical Trial Plans: Oncolytics plans to launch a controlled study in March 2026 comparing standard care versus standard care plus pelareorep, with interim data expected by year-end, laying the groundwork for future product line expansion.
- Leadership Team Expansion: Oncolytics Biotech has recently appointed two key executives to oversee strategy and biostatistics, aiming to strengthen the company's leadership in the rapidly evolving biopharmaceutical landscape to meet the increasing demands of clinical trials.
See More
Autolus Therapeutics Reports Strong 2025 Earnings with AUCATZYL Launch Success
- AUCATZYL Sales Performance: Autolus Therapeutics achieved $74.3 million in AUCATZYL sales for 2025, marking a successful U.S. launch with 67 centers activated by year-end, indicating strong market demand and positive physician feedback.
- 2026 Financial Outlook: Management reiterated guidance for 2026 net revenue between $120 million and $135 million, expecting a shift to positive gross margins and activation of over 80 centers by year-end, reflecting confidence in future growth.
- Clinical Data Support: The ROCCA Consortium reported a 92% overall complete remission rate at day 28 for 91 patients treated with AUCATZYL, closely aligning with prior clinical trial data, which further bolsters physician confidence and market acceptance.
- R&D and Financial Status: Q4 2025 net product revenue was $23.3 million, with R&D expenses at $35.6 million; despite an operating loss of $72.5 million, the company maintains $300.7 million in cash and equivalents, sufficient to fund operations into Q4 2027.
See More
AUCATZYL® 2025 Financial Results and Market Outlook
- Revenue Growth: AUCATZYL® reported net product revenue of $23.3 million for Q4 2025 and $74.3 million for the full year, indicating strong demand in the U.S. market, which is expected to drive future revenue growth for Autolus.
- UK Market Launch: Following a successful evaluation by the National Institute for Health and Care Excellence (NICE), AUCATZYL® was launched in the UK in January 2026, marking a significant step in the company's international expansion strategy and is anticipated to further enhance market share.
- Positive Outlook: Autolus projects net product revenue for AUCATZYL® to range between $120 million and $135 million in 2026, with expectations of achieving a positive gross margin, reflecting positive changes in operational efficiency and market demand.
- Clinical Trial Progress: AUCATZYL® has demonstrated a favorable safety and efficacy profile in multiple clinical trials, particularly in pediatric patients with relapsed/refractory B-ALL, where preliminary data shows an overall response rate of 95.5%, laying a solid foundation for future market promotion.
See More
Autolus Therapeutics Q4 Earnings Report Analysis
- Disappointing Earnings: Autolus Therapeutics reported a Q4 GAAP EPS of -$0.34, missing expectations by $0.07, indicating challenges in profitability that may affect investor confidence.
- Revenue Beat: Despite the EPS miss, Q4 revenue reached $24.29 million, exceeding market expectations by $0.37 million, suggesting that the company still possesses some growth potential in sales.
- Cautious Future Outlook: As FY 2025 earnings approach, market expectations regarding Autolus's profitability and revenue growth will be closely monitored, requiring investors to assess the company's positioning in the competitive biopharmaceutical market.
- Analyst Rating Dynamics: Seeking Alpha's Quant Rating on Autolus Therapeutics reflects market divergence regarding its future performance, highlighting differing investor perspectives on the company's long-term strategy and financial health.
See More
Autolus Therapeutics Earnings Announcement Scheduled
- Earnings Release Date: Autolus Therapeutics is set to announce its FY earnings on March 27 before market open, with investors keenly awaiting performance insights to gauge future growth potential.
- EPS Expectations: The consensus EPS estimate stands at -$0.43, reflecting a 50% year-over-year improvement, indicating the company's efforts to enhance profitability, albeit still facing losses.
- Significant Revenue Growth: The consensus revenue estimate is $74.75 million, representing a substantial year-over-year increase of 638.6%, showcasing the company's strong performance in market demand and product sales.
- Performance Revision Insights: Over the past year, Autolus has only beaten EPS estimates 25% of the time, with no revenue estimates surpassed, highlighting market uncertainty regarding its profitability trajectory.
See More
Precision Biologics Market Awakens to $71 Billion Opportunity
- FDA Acceleration: Oncolytics Biotech's cancer treatment pelareorep has received Fast Track Designation from the FDA for KRAS-mutant microsatellite-stable metastatic colorectal cancer patients, demonstrating a 33% response rate significantly higher than the 10% seen with traditional chemotherapy, which will expedite its approval process and enhance market competitiveness.
- Survival Extension: Clinical data shows that patients treated with pelareorep have a median survival of 27 months compared to 11.2 months with standard treatment, indicating the drug's potential market value in hard-to-treat cancer populations, with the global second-line treatment market estimated between $3 billion and $5 billion annually.
- Leadership Team Expansion: Oncolytics Biotech recently appointed John McAdory as Executive Vice President of Strategy and Operations and Yujun Wu as Vice President of Biostatistics to manage expanding clinical programs, reflecting the company's commitment to future growth and readiness.
- Clinical Trial Plans: The company plans to launch a controlled study in March 2026 comparing standard treatment with pelareorep, with interim data expected by year-end, further validating its efficacy in colorectal cancer treatment.
See More
Precision Biologics Market Awakens to $71 Billion Opportunity
- FDA Acceleration: Oncolytics Biotech's cancer treatment pelareorep has received Fast Track Designation from the FDA for KRAS-mutant microsatellite-stable metastatic colorectal cancer patients, demonstrating a 33% response rate, significantly higher than the 10% achieved with traditional chemotherapy, which will expedite its market entry and enhance the company's position in the competitive biopharmaceutical sector.
- Significant Survival Extension: Clinical data shows that patients treated with pelareorep have a median survival of 27 months compared to 11.2 months with standard treatment, indicating the drug's potential market value in hard-to-treat cancer populations, with the global second-line treatment market estimated between $3 billion and $5 billion annually.
- Clinical Trial Plans: Oncolytics plans to launch a controlled study in March 2026 comparing standard care versus standard care plus pelareorep, with interim data expected by year-end, laying the groundwork for future product line expansion.
- Leadership Team Expansion: Oncolytics Biotech has recently appointed two key executives to oversee strategy and biostatistics, aiming to strengthen the company's leadership in the rapidly evolving biopharmaceutical landscape to meet the increasing demands of clinical trials.
See More
